Abbott Laboratories Ordered to Pay $70M in Infant Formula NEC Trial

What happened

On April 9–10, a Cook County jury awarded $70 million in total damages—$53 million compensatory and $17 million punitive—against Abbott Laboratories in a case brought by four families. The jury determined that Abbott's cow's-milk-based Similac formula caused their premature infants to develop necrotizing enterocolitis (NEC), a severe intestinal disease that leads to inflammation, tissue death, and sometimes intestinal perforation. All four infants suffered severe, lasting complications, with three requiring surgery. Plaintiffs' attorneys argued Abbott was aware of the increased risk NEC posed to premature babies but failed to provide adequate warnings to parents or healthcare providers.

Why it matters

This verdict is the first major state court loss for Abbott in Cook County and adds to a growing wave of litigation that could reshape how infant formula is labeled and marketed. NEC affects premature babies disproportionately and carries a fatality rate of 15–40%. The lawsuit underscores ongoing legal and regulatory scrutiny surrounding whether formula manufacturers have sufficiently communicated known risks. While Abbott has successfully defended similar cases in federal court—where judges ruled benefits outweigh risks under federal evidence standards—state courts apply more plaintiff-friendly rules, allowing cases to proceed. Abbott plans to appeal, citing that the verdict contradicts the medical consensus supporting the safety of preterm formulas.

Bigger picture

Thousands of similar lawsuits are pending nationwide against Abbott and peer Mead Johnson, alleging inadequate warnings about NEC risk. Federal judges have dismissed several cases, reasoning that formulas serve a critical role when human milk is unavailable. However, juries in state courts—including a 2024 St. Clair County $60 million verdict and a Missouri $495 million award—have sided with plaintiffs. Industry executives and healthcare providers warn that continued high-stakes verdicts could threaten formula availability if manufacturers face billions in damages or alter product lines. Abbott remains under investigation by the SEC and FTC regarding its formula business practices.

What to watch

Investors should monitor Abbott's appeal process and future trial outcomes, particularly in plaintiff-friendly Illinois state courts where hundreds of cases remain docketed. Watch for regulatory actions or label changes that could result from mounting legal pressure. Also track whether federal versus state court divergence prompts legislative or regulatory intervention, and assess potential impacts on Abbott's infant nutrition segment profitability and market position.

This article was generated by Quantli AI using publicly available news sources.